KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

Company Overview

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema. These candidates are designed to address unmet needs in rare disease and ophthalmology by improving patient convenience, reducing the burden of disease manifestations and potentially offering long‐lasting therapeutic benefit.

Founded in 2010 and headquartered in Cambridge, England, KalVista also maintains operations in Boston, Massachusetts. The company completed its initial public offering on the Nasdaq exchange in 2015 and has since advanced its pipeline through a combination of in‐house research, strategic collaborations and contract manufacturing partnerships. KalVista’s programs target patient populations in North America, Europe and other markets with significant unmet medical need.

KalVista is led by President and Chief Executive Officer Anna Berkenstock, PhD, who brings extensive experience in drug discovery, development and corporate strategy. The broader leadership team and board of directors draw on deep expertise in rare disease biology, protease chemistry and clinical development to guide the company’s strategic priorities and global growth.

Key Stats

• Today's Range: $27.00 to $27.00
• 50-Day Range: $26.71 to $27.00
• 52-Week Range: $9.83 to $27.00
• Volume: N/A
• Average Volume: 3.07 million shs
• Market Capitalization: $1.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.25
• Consensus Rating: Hold

KalVista Pharmaceuticals Stock Analysis - MarketRank™

KalVista Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat, and ranked 797th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

KalVista Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 3 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

KalVista Pharmaceuticals has a consensus price target of $33.25, representing about 23.1% upside from its current price of $27.00.

Amount of Analyst Coverage

KalVista Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($1.19) to $0.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of KalVista Pharmaceuticals is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KalVista Pharmaceuticals is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KalVista Pharmaceuticals has a P/B Ratio of 9.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KALV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KalVista Pharmaceuticals does not currently pay a dividend.

Dividend Growth

KalVista Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for KALV on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, KalVista Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.30% of the stock of KalVista Pharmaceuticals is held by insiders.

Percentage Held by Institutions

KalVista Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 10/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:KALV
• CIK: 1348911
• Web: www.kalvista.com
• Phone: 857-999-0075
• Fax: 866-553-3269
• Employees: 100
• Year Founded: 2011

Price Target and Rating

• Average Price Target for KalVista Pharmaceuticals: $33.25
• High Price Target: $42.00
• Low Price Target: $27.00
• Potential Upside/Downside: +23.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109.52 million
• Net Margins: N/A
• Pretax Margin: -1,290.65%
• Return on Equity: -341.44%
• Return on Assets: -111.94%

Debt

• Debt-to-Equity Ratio: 8.18
• Current Ratio: 5.17
• Quick Ratio: 5.10

Sales & Book Value

• Annual Sales: $1.43 million
• Price / Sales: 1,008.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 9.96

Miscellaneous

• Outstanding Shares: 53,241,000
• Free Float: 50,952,000
• Market Cap: $1.44 billion
• Optionable: Optionable
• Beta: -0.12